NEA’s David Mott on what VC firm’s $2.6B fund means for biotech (biotechVC)

New Enterprise   Associates   packs financial firepower like few other venture capital outfits today,   particularly those investing in biotech. Fresh off closing a diversified   venture fund of $2.6 billion revealed in July, NEA is expected to spend   roughly a third of its capital from the fund on healthcare investments   primarily in the biopharma industry, General Partner David Mott   (who sold MedImmune to   AstraZeneca ($AZN)   for $15.6 billion in 2007), told FierceBiotech.Continue reading

Living with an Artificial Heart

SynCardia Publishes 1st Brochure for Total Artificial Heart Patients & Their Caregivers

12-Page Resource Describes How the Total Artificial Heart Works, What to Expect Before & After Surgery and the Steps to Patient Discharge Using the Freedom® DriverContinue reading

Jennifer Kehlet Barton, Ph.D. named 2012 Michael A. Cusanovich Bioscience Educator of the Year

Jennifer Kehlet Barton, Ph.D., Associate Vice President for Research and Professor, Biomedical Engineering at The University of Arizona has been named the 2012 Michael A. Cusanovich Bioscience Educator of the Year by the Arizona Bioindustry Association.

She will receive her award October 23, 2012 during the 2012 AZBio Awards which will be held at the Phoenix Convention Center and draw bioscience leaders from across the state of Arizona.Continue reading